TWI791423B - C3腎絲球病變之治療方法 - Google Patents

C3腎絲球病變之治療方法 Download PDF

Info

Publication number
TWI791423B
TWI791423B TW106100938A TW106100938A TWI791423B TW I791423 B TWI791423 B TW I791423B TW 106100938 A TW106100938 A TW 106100938A TW 106100938 A TW106100938 A TW 106100938A TW I791423 B TWI791423 B TW I791423B
Authority
TW
Taiwan
Prior art keywords
compound
group
treatment
human
independently selected
Prior art date
Application number
TW106100938A
Other languages
English (en)
Chinese (zh)
Other versions
TW201726134A (zh
Inventor
佩脫拉斯 貝克
Original Assignee
美商卡默森屈有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商卡默森屈有限公司 filed Critical 美商卡默森屈有限公司
Publication of TW201726134A publication Critical patent/TW201726134A/zh
Application granted granted Critical
Publication of TWI791423B publication Critical patent/TWI791423B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
TW106100938A 2016-01-14 2017-01-12 C3腎絲球病變之治療方法 TWI791423B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662278788P 2016-01-14 2016-01-14
US62/278,788 2016-01-14
US201662280346P 2016-01-19 2016-01-19
US62/280,346 2016-01-19
US201662347450P 2016-06-08 2016-06-08
US62/347,450 2016-06-08
US201662397527P 2016-09-21 2016-09-21
US62/397,527 2016-09-21

Publications (2)

Publication Number Publication Date
TW201726134A TW201726134A (zh) 2017-08-01
TWI791423B true TWI791423B (zh) 2023-02-11

Family

ID=59312069

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106100938A TWI791423B (zh) 2016-01-14 2017-01-12 C3腎絲球病變之治療方法

Country Status (18)

Country Link
US (3) US20170202821A1 (cg-RX-API-DMAC7.html)
EP (1) EP3402486B1 (cg-RX-API-DMAC7.html)
JP (4) JP7339733B2 (cg-RX-API-DMAC7.html)
KR (1) KR102767008B1 (cg-RX-API-DMAC7.html)
CN (1) CN108601790A (cg-RX-API-DMAC7.html)
AU (1) AU2017207359C1 (cg-RX-API-DMAC7.html)
BR (2) BR122024002810A2 (cg-RX-API-DMAC7.html)
CA (1) CA3010735C (cg-RX-API-DMAC7.html)
ES (1) ES3026359T3 (cg-RX-API-DMAC7.html)
IL (1) IL260539B (cg-RX-API-DMAC7.html)
MA (1) MA43872A (cg-RX-API-DMAC7.html)
MX (2) MX2018008624A (cg-RX-API-DMAC7.html)
NZ (1) NZ744083A (cg-RX-API-DMAC7.html)
RU (1) RU2742888C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201805828YA (cg-RX-API-DMAC7.html)
TW (1) TWI791423B (cg-RX-API-DMAC7.html)
WO (1) WO2017123716A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201804513B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
KR102593431B1 (ko) 2014-09-29 2023-10-23 케모센트릭스, 인크. Ｃ5ａＲ 길항제의 제조 방법 및 이러한 제조에서의 중간체
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
SG11201805828YA (en) 2016-01-14 2018-08-30 Chemocentryx Inc Method of treating c3 glomerulopathy
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
MX2019010381A (es) 2017-03-01 2020-01-21 Achillion Pharmaceuticals Inc Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
WO2019021091A1 (en) * 2017-07-27 2019-01-31 Procter & Gamble International Operations Sa SPRAYABLE, STABLE PHASE REFRIGERATING COMPOSITIONS COMPRISING SUSPENDED PARTICLES
WO2019028284A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
EP3814374A4 (en) * 2018-05-25 2022-03-09 Achillion Pharmaceuticals, Inc. NEPHROPATHY BIOMARKERS ASSOCIATED WITH COMPLEMENT ALTERNATIVE PATHWAY
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
ES2943492T3 (es) 2018-11-30 2023-06-13 Chemocentryx Inc Formulación de cápsulas
AU2019406830A1 (en) 2018-12-17 2021-07-08 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
CN119874606A (zh) 2019-03-11 2025-04-25 因弗拉克斯有限责任公司 作为C5a受体调节剂的稠合哌啶基双环和相关化合物
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
KR20230050364A (ko) * 2020-08-07 2023-04-14 키라 파마슈티칼스 (수조우) 엘티디. C5ar 억제제로서의 화합물
KR20230124981A (ko) * 2020-12-21 2023-08-28 케모센트릭스, 인크. C5a 억제제를 사용한 c3 사구체병증의 치료
CN115192563B (zh) * 2022-05-09 2023-10-13 北京大学第一医院 C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225056A1 (en) * 2008-11-10 2012-09-06 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US8845515B2 (en) * 2011-01-17 2014-09-30 Coloplast A/S Penile implant with dilatant liquid

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
IL141724A0 (en) 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
RU2197288C2 (ru) * 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
AU2001259511A1 (en) 2000-05-05 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
ES2353077T3 (es) 2000-08-10 2011-02-25 Mitsubishi Tanabe Pharma Corporation Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
CN1474803B (zh) 2000-09-14 2012-11-21 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
JP5260818B2 (ja) 2000-09-29 2013-08-14 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 高親和性低分子Ｃ５ａ受容体調節物質
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
BR0212892A (pt) 2001-09-21 2004-08-03 Mitsubishi Pharma Corp Derivados de 4-pirimidona-3-substituìdo
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
JP2006508894A (ja) 2002-03-28 2006-03-16 ニューロジェン・コーポレーション Ｃ５ａ受容体調節因子としての置換テトラヒドロイソキノリン
US20040014782A1 (en) 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
AU2003257094A1 (en) 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
WO2004018460A1 (en) 2002-08-21 2004-03-04 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
US7455837B2 (en) 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CN101163693B (zh) 2005-02-18 2013-03-06 阿斯利康(瑞典)有限公司 抗菌哌啶衍生物
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
HUE031466T2 (hu) 2005-11-24 2017-07-28 Dompe Farm Spa (R)-arilalkilamino származékok és azokat tartalmazó gyógyászati készítmények
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
EP2077842A2 (en) * 2006-10-31 2009-07-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an egfr antagonist for the treatment of glomerolonephritis
AU2008272437A1 (en) 2007-06-29 2009-01-08 Torrent Pharmaceuticals Ltd. Novel substituted piperidones as HSP inducers
US9284297B2 (en) 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
WO2011035143A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Methods and compositions for inhibiting rho-mediated diseases and conditions
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
US9452990B2 (en) * 2012-06-20 2016-09-27 Novartis Ag Complement pathway modulators and uses thereof
CN105392803B (zh) 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
KR102593431B1 (ko) 2014-09-29 2023-10-23 케모센트릭스, 인크. Ｃ5ａＲ 길항제의 제조 방법 및 이러한 제조에서의 중간체
SG11201805828YA (en) 2016-01-14 2018-08-30 Chemocentryx Inc Method of treating c3 glomerulopathy
JP7121722B2 (ja) 2016-04-04 2022-08-18 ケモセントリックス，インコーポレイティド 可溶性Ｃ５ａＲアンタゴニスト
KR20230124981A (ko) 2020-12-21 2023-08-28 케모센트릭스, 인크. C5a 억제제를 사용한 c3 사구체병증의 치료

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225056A1 (en) * 2008-11-10 2012-09-06 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US8845515B2 (en) * 2011-01-17 2014-09-30 Coloplast A/S Penile implant with dilatant liquid

Also Published As

Publication number Publication date
EP3402486A1 (en) 2018-11-21
CA3010735C (en) 2023-06-13
ZA201804513B (en) 2024-01-31
AU2017207359C1 (en) 2022-09-01
RU2018129378A (ru) 2020-02-14
IL260539B (en) 2021-05-31
JP2024110998A (ja) 2024-08-16
EP3402486A4 (en) 2019-08-28
KR20180102642A (ko) 2018-09-17
AU2017207359A1 (en) 2018-07-26
EP3402486B1 (en) 2025-03-19
BR112018014222A2 (pt) 2018-12-11
BR122024002810A2 (pt) 2024-03-12
TW201726134A (zh) 2017-08-01
US20170202821A1 (en) 2017-07-20
US20220354837A1 (en) 2022-11-10
US11285138B2 (en) 2022-03-29
JP2019501935A (ja) 2019-01-24
CN108601790A (zh) 2018-09-28
MA43872A (fr) 2021-05-19
NZ744083A (en) 2022-07-01
KR102767008B1 (ko) 2025-02-11
JP2021183625A (ja) 2021-12-02
EP3402486C0 (en) 2025-03-19
AU2017207359B2 (en) 2022-04-14
MX2022006069A (es) 2023-01-12
WO2017123716A1 (en) 2017-07-20
CA3010735A1 (en) 2017-07-20
JP7788814B2 (ja) 2025-12-19
RU2018129378A3 (cg-RX-API-DMAC7.html) 2020-05-20
US11779576B2 (en) 2023-10-10
MX2018008624A (es) 2018-12-10
ES3026359T3 (en) 2025-06-11
JP2023126235A (ja) 2023-09-07
SG11201805828YA (en) 2018-08-30
US20190201388A1 (en) 2019-07-04
RU2742888C2 (ru) 2021-02-11
JP7339733B2 (ja) 2023-09-06

Similar Documents

Publication Publication Date Title
TWI791423B (zh) C3腎絲球病變之治療方法
KR102395093B1 (ko) 가용성 C5aR 길항제
KR20200109297A (ko) 소변 sCD163의 C5aR 억제제 감소
US20220257580A1 (en) Treatment of c3 glomerulopathy using a c5a inhibitor
HK1262045A1 (en) Ccx168 for use in the treatment of c3 glomerulopathy
HK1262045B (en) Ccx168 for use in the treatment of c3 glomerulopathy
HK40089184A (zh) 使用c5a抑制剂治疗c3肾小球病
HK40004502B (en) Soluble c5ar antagonists